Recombinant bacterial ghosts: Versatile targeting vehicles and promising vaccine candidates

International Journal of Medical Microbiology

Volumn 294, Issue 5, 2004, Pages 303-311

  Hoffelner, Herbert ^a   Haas, Rainer ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; GLYCOPROTEIN GP 91; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; OUTER MEMBRANE PROTEIN; RECOMBINANT ANTIGEN;

ANIMAL EXPERIMENT; BACTERIAL CELL; BACTERIAL GENE; DRUG DELIVERY SYSTEM; DRUG TARGETING; GENE EXPRESSION REGULATION; HELICOBACTER PYLORI; MOUSE; NONHUMAN; PHIX174 LYSIS GENE E; REVIEW; VACCINATION;

EID: 6044267867     PISSN: 14384221     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijmm.2004.04.003     Document Type: Review

References (48)

1. Astarie-Dequeker, C., N'Diaye, E.N., Le, C.V., Rittig, M.G., Prandi, J., Maridonneau-Parini, I., 1999. The mannose receptor mediates uptake of pathogenic and nonpathogenic mycobacteria and bypasses bactericidal responses in human macrophages. Infect. Immun. 67, 469-477.
2. Blaser, M.J., Berg, D.E., 2001. Helicobacter pylori genetic diversity and risk of human disease. J. Clin. Invest. 107, 767-773.
3. Chiers, K., Donne, E., Van Overbeke, I., Ducatelle, R., Haesebrouck, F., 2002. Evaluation of serology, bacteriological isolation and polymerase chain reaction for the detection of pigs carrying Actinobacillus pleuropneumoniae in the upper respiratory tract after experimental infection. Vet. Microbiol. 88, 385-392.
4. Corthesy-Theulaz, I., Porta, N., Glauser, M., Saraga, E., Vaney, A.C., Haas, R., Kraehenbuhl, J.P., Blum, A.L., Michetti, P., 1995. Oral immunization with Helicobacter pylori urease B subunit as a treatment against Helicobacter infection in mice. Gastroenterology 109, 115-121.
5. Czinn, SJ., Nedrud, J.G., 1991. Oral immunization against Helicobacter pylori. Infect. Immun. 59, 2359-2363.
6. Del Giudice, G., Covacci, A., Telford, J.L., Montecucco, C., Rappuoli, R., 2001. The design of vaccines against Helicobacter pylori and their development. Annu. Rev. Immunol. 19, 523-563.
7. Eko, P.O., Hensel, A., Bunka, S., Lubitz, W., 1994a. Immunogenicity of Vibrio cholerae ghosts following intraperitoneal immunization of mice. Vaccine 12, 1330-1334.
8. Eko, P.O., Udo, S.M., Antia-Obong, O.E., 1994b. Epidemiology and spectrum of vibrio diarrheas in the lower cross river basin of Nigeria. Centr. Eur. J. Public Health 2, 37-41.
9. Eko, P.O., Mayr, U.B., Attridge, S.R., Lubitz, W., 2000. Characterization and immunogenicity of Vibrio cholerae ghosts expressing toxin-coregulated pili. J. Biotechnol. 83, 115-123.
10. Eko, P.O., Lubitz, W., McMillan, L., Ramey, K., Moore, T.T., Ananaba, G.A., Lyn, D., Black, C.M., Igietseme, J.U., 2003a. Recombinant Vibrio cholerae ghosts as a delivery vehicle for vaccinating against Chlamydia trachomatis. Vaccine 21, 1694-1703.
11. Eko, F.O., Schukovskaya, T., Lotzmanova, E.Y., Firstova, V.V., Emalyanova, N.V., Klueva, S.N., Kravtzov, A.L., Livanova, L.F., Kutyrev, V.V., Igietseme, J.U., Lubitz, W., 2003b. Evaluation of the protective efficacy of Vibrio cholerae ghost (VCG) candidate vaccines in rabbits. Vaccine 21,3663-3674.
12. Ferrero, R.L., Thiberge, J.M., Huerre, M., Labigne, A., 1994. Recombinant antigens prepared from the urease subunits of Helicobacter spp: evidence of protection in a mouse model of gastric infection. Infect. Immun. 62, 4981-4989.
13. Gomez-Duarte, O.G., Bumann, D., Meyer, T.F., 1999. The attenuated Salmonella vaccine approach for the control of Helicobacter pylori-related diseases. Vaccine 17, 1667-1673.
14. Gröger, M., Holnthoner, W., Maurer, D., Lechleitner, S., Wolff, K., Mayr, B.B., Lubitz, W., Petzelbauer, P., 2000. Dermalmicrovascular endothelial cells express the 180-kDa macrophage mannose receptor in situ and in vitro. J. Immunol. 165, 5428-5434.
15. Haslberger, A.G., Kohl, G., Felnerova, D., Mayr, U.B., Furst-Ladani, S., Lubitz, W., 2000. Activation, stimulation and uptake of bacterial ghosts in antigen presenting cells. J. Biotechnol. 83, 57-66.
16. Hensel, A., van Leengoed, L.A., Szostak, M., Windt, H., Weissenbock, H., Stockhofe-Zurwieden, N., Katinger, A., Stadler, M., Ganter, M., Bunka, S., Pabst, R., Lubitz, W., 1996. Induction of protective immunity by aerosol or oral application of candidate vaccines in a dose-controlled pig aerosol infection model. J. Biotechnol. 44, 171-181.
17. Hensel, A., Huter, V., Katinger, A., Raza, P., Strnistschie, C., Roesler, U., Brand, E., Lubitz, W., 2000. Intramuscular immunization with genetically inactivated (ghosts) Actinobacillus pleuropneumoniae serotype 9 protects pigs against homologous aerosol challenge and prevents carrier state. Vaccine 18, 2945-2955.
18. Hess, J., Kaufmann, S.H., 1999. Live antigen carriers as tools for improved anti-tuberculosis vaccines. FEMS Immunol. Med. Microbiol. 23, 165-173.
19. Huter, V., Hensel, A., Brand, E., Lubitz, W., 2000. Improved protection against lung colonization by Actinobacillus pleuropneumoniae ghosts: characterization of a genetically inactivated vaccine. J. Biotechnol. 83, 161-172.
20. IARC, 1994. IARC monographs on the evaluation of carcinogenic risks to humans. International Agency for Research on cancer, World Health Organization, Lyon.
21. Jalava, K., Hensel, A., Szostak, M., Resch, S., Lubitz, W., 2002. Bacterial ghosts as vaccine candidates for veterinary applications. J. Control Release 85, 17-25.
22. Jalava, K., Eko, F.O., Riedmann, E., Lubitz, W., 2003. Bacterial ghosts as carrier and targeting systems for mucosal antigen delivery. Expert. Rev. Vaccines 2, 45-51.
23. Jechlinger, W., Szostak, M.P., Lubitz, W., 1998. Cold-sensitive E-lysis systems. Gene 218, 1-7.
24. Jechlinger, W., Szostak, M.P., Witte, A., Lubitz, W., 1999. Altered temperature induction sensitivity of the lambda pR/cI857 system for controlled gene E expression in Escherichia coli. FEMS Microbiol. Lett. 173, 347-352.
25. Katinger, A., Lubitz, W., Szostak, M.P., Stadler, M., Klein, R., Indra, A., Huter, V., Hensel, A., 1999. Pigs aerogenously immunized with genetically inactivated (ghosts) or irradiated Actinobacillus pleuropneumoniae are protected against a homologous aerosol challenge despite differing in pulmonary cellular and antibody responses. J. Biotechnol. 73, 251-260.
26. Kotloff, K.L., Sztein, M.B., Wasserman, S.S., Losonsky, G.A., DiLorenzo, S.C., Walker, R.I., 2001. Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect. Immun. 69, 3581-3590.
27. Lee, A., Fox, J., Hazell, S., 1993. Pathogenicity of Helicobacter pylori: a perspective. Infect. Immun. 61, 1601-1610.
28. Marchart, J., Dropmann, G., Lechleitner, S., Schlapp, T., Wanner, G., Szostak, M.P., Lubitz, W., 2003a. Pasteurella multocida- and Pasteurella haemolytica-ghosts: new vaccine candidates. Vaccine 21, 3988-3997.
29. Marchart, J., Rehagen, M., Dropmann, G., Szostak, M.P., Alldinger, S., Lechleitner, S., Schlapp, T., Resch, S., Lubitz, W., 2003b. Protective immunity against pasteurellosis in cattle, induced by Pasteurella haemolytica ghosts. Vaccine 21, 1415-1422.
30. Michetti, P., Corthesy-Theulaz, I., Davin, C., Haas, R., Vaney, A.C., Heitz, M., Bille, J., Kraehenbuhl, J.P., Saraga, E., Blum, A.L., 1994. Immunization of BALB/c mice against Helicobacter felis infection with Helicobacter pylori urease. Gastroenterology 107, 1002-1011.
31. Michetti, P., Kreiss, C., Kotloff, K.L., Porta, N., Blanco, J.L., Bachmann, D., Herranz, M., Saldinger, P.F., Corthesy-Theulaz, I., Losonsky, G., Nichols, R., Simon, J., Stolte, M., Ackerman, S., Monath, T.P., Blum, A.L., 1999. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology 116, 804-812.
32. Murray, C.J., Lopez, A.D., 1997. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 349, 1498-1504.
33. Panthel, K., Jechlinger, W., Malis, A., Rohde, M., Szostak, M., Lubitz, W., Haas, R., 2003. Generation of Helicobacter pylori ghosts by PhiX protein E-mediated inactivation and their evaluation as vaccine candidates. Infect. Immun. 71, 109-116.
34. Pisani, P., Parkin, D.M., Ferlay, J., 1993. Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int. J. Cancer 55, 891-903.
35. Radcliff, F.J., Hazell, S.L., Kolesnikow, T., Doidge, C., Lee, A., 1997. Catalase, a novel antigen for Helicobacter pylori vaccination. Infect. Immun. 65, 4668-4674.
36. Riedmann, E.M., Kyd, J.M., Smith, A.M., Gomez-Gallego, S., Jalava, K., Cripps, A.W., Lubitz, W., 2003. Construction of recombinant S-layer proteins (rSbsA) and their expression in bacterial ghosts - a delivery system for the nontypeable Haemophilus influenzae antigen Omp26. FEMS Immunol. Med. Microbiol. 37, 185-192.
37. Rüssmann, H., Shams, H., Poblete, F., Fu, Y., Galan, J.E., Donis, R.O., 1998. Delivery of epitopes by the Salmonella type III secretion system for vaccine development. Science 281, 565-568.
38. Sallusto, F., Cella, M., Danieli, C., Lanzavecchia, A., 1995. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: down-regulation by cytokines and bacterial products. J. Exp. Med. 182, 389-400.
39. Schroll, G., Resch, S., Gruber, K., Wanner, G., Lubitz, W., 1998. Heterologous phi X174 gene E-expression in Ralstonia eutropha: E-mediated lysis is not restricted to gamma-subclass of proteobacteria. J. Biotechnol. 66, 211-217.
40. Sutton, P., Lee, A., 2000. Helicobacter pylori vaccines - the current status. Aliment. Pharmacol. Ther. 14, 1107-1118.
41. Szostak, M.P., Hensel, A., Eko, P.O., Klein, R., Auer, T., Mader, H., Haslberger, A., Bunka, S., Wanner, G., Lubitz, W., 1996. Bacterial ghosts: non-living candidate vaccines. J. Biotechnol. 44, 161-170.
42. Szostak, M.P., Mader, H., Truppe, M., Kamal, M., Eko, F.O., Huter, V., Marchart, J., Jechlinger, W., Haidinger, W., Brand, E., Denner, E., Resch, S., Dehlin, E., Katinger, A., Kuen, B., Haslberger, A., Hensel, A., Lubitz, W., 1997. Bacterial ghosts as multifunctional vaccine particles. Behring Inst. Mitt., pp. 191-196.
43. Taylor, R.K., 1991. Bacterial adhesion to mucosal surfaces. J. Chemother. 3 (Suppl 1), 190-195.
44. Torres, A.G., Giron, J.A., Perna, N.T., Burland, V., Blattner, F.R., Avelino-Flores, F., Kaper, J.B., 2002. Identification and characterization of lpfABCC'DE, a fimbrial operon of enterohemorrhagic Escherichia coli O157:H7. Infect. Immun. 70, 5416-5427.
45. Witte, A., Blasi, U., Halfmann, G., Szostak, M., Wanner, G., Lubitz, W., 1990a. Phi X174 protein E-mediated lysis of Escherichia coll. Biochimie 72, 191-200.
46. Witte, A., Wanner, G., Blasi, U., Halfmann, G., Szostak, M., Lubitz, W., 1990b. Endogenous transmembrane tunnel formation mediated by phi X174 lysis protein E. J. Bacteriol. 172, 4109-4114.
47. Witte, A., Wanner, G., Sulzner, M., Lubitz, W., 1992. Dynamics of PhiX174 protein A-mediated lysis of Escherichia coli. Arch. Microbiol. 157, 381-388.
48. Witte, A., Wanner, G., Lubitz, W., Holtje, J.V., 1998. Effect of phi X174 protein E-mediated lysis on murein composition of Escherichia coli. FEMS Microbiol. Lett. 164, 149-157.